Preclinical Drug Development Articles & Analysis
7 articles found
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. ...
Alfa Cytology unveils advanced cancer immunotherapy development services. Alfa Cytology, a renowned services supplier in oncology, has recently introduced its groundbreaking cancer immunotherapy development services. This initiative signifies a major leap forward in the development of more effective cancer therapies, aiming to boost both ...
The evaluation of cardiovascular toxicity is a significant challenge in drug development. Preclinical evaluation of cardiovascular safety involves a multifaceted approach, encompassing a plethora of in vitro and in vivo endpoints. ...
The service encompasses the entire preclinical development lifecycle of therapeutic antibodies—ranging from initial conceptualization and engineering to rigorous quality assurance assessments. ...
In the world of pharmaceuticals, developing safe and effective drugs is a complex and time-consuming process. ...
Understanding the functional characteristics and cellular tropism of SARS-CoV-2, as well as the pathogenesis leading to multi-organ failure and death, has driven the unprecedented adoption of organoid models. Successful drug discovery and vaccine development rely on preclinical models that faithfully recapitulate the viral life cycle and host ...
Prediction of the first-in-human dosing regimens is a critical step in drug development and requires accurate quantitation of drug distribution. ...